BACKGROUND: Recent studies show links between metabolic syndrome and Alzheimer's disease (AD) neuropathology. Understanding the link between vascular-related health conditions and dementia will help target at risk populations and inform clinical strategies for early detection and prevention of AD. OBJECTIVE: To determine whether metabolic syndrome is associated with global cerebral amyloid-β (Aβ) positivity and longitudinal Aβ accumulation. METHODS: Prospective study of 165 participants who underwent (11)C-Pittsburgh compound B (PiB) PET neuroimaging to measure Aβ, from June 2005 to May 2016. Metabolic syndrome was defined using the revised Third Adults Treatment Panel of the National Cholesterol Education Program criteria. Participants were classified as PiB+/-. Linear mixed effects models assessed the relationships between baseline metabolic syndrome and PiB status and regional Aβ change over time. RESULTS: A total of 165 cognitively normal participants of the Baltimore Longitudinal Study of Aging (BLSA) Neuroimaging substudy, aged 55-92 years (mean baseline age = 76.4 years, 85 participants were male), received an average of 2.5 PET-PiB scans over an average interval of 2.6 (3.08 SD) years between first and last visits. Metabolic syndrome was not associated with baseline PiB positivity or concurrent regional Aβ. Metabolic syndrome was associated with increased rates of Aβ accumulation in superior parietal and precuneus regions over time in the PiB+ group. Elevated fasting glucose and blood pressure showed individual associations with accelerated Aβ accumulation. CONCLUSION: Metabolic syndrome was associated with accelerated Aβ accumulation in PiB+ individuals and may be an important factor in the progression of AD pathology.
BACKGROUND: Recent studies show links between metabolic syndrome and Alzheimer's disease (AD) neuropathology. Understanding the link between vascular-related health conditions and dementia will help target at risk populations and inform clinical strategies for early detection and prevention of AD. OBJECTIVE: To determine whether metabolic syndrome is associated with global cerebral amyloid-β (Aβ) positivity and longitudinal Aβ accumulation. METHODS: Prospective study of 165 participants who underwent (11)C-Pittsburgh compound B (PiB) PET neuroimaging to measure Aβ, from June 2005 to May 2016. Metabolic syndrome was defined using the revised Third Adults Treatment Panel of the National Cholesterol Education Program criteria. Participants were classified as PiB+/-. Linear mixed effects models assessed the relationships between baseline metabolic syndrome and PiB status and regional Aβ change over time. RESULTS: A total of 165 cognitively normal participants of the Baltimore Longitudinal Study of Aging (BLSA) Neuroimaging substudy, aged 55-92 years (mean baseline age = 76.4 years, 85 participants were male), received an average of 2.5 PET-PiB scans over an average interval of 2.6 (3.08 SD) years between first and last visits. Metabolic syndrome was not associated with baseline PiB positivity or concurrent regional Aβ. Metabolic syndrome was associated with increased rates of Aβ accumulation in superior parietal and precuneus regions over time in the PiB+ group. Elevated fasting glucose and blood pressure showed individual associations with accelerated Aβ accumulation. CONCLUSION:Metabolic syndrome was associated with accelerated Aβ accumulation in PiB+ individuals and may be an important factor in the progression of AD pathology.
Authors: Ira Driscoll; Susan M Resnick; Juan C Troncoso; Yang An; Richard O'Brien; Alan B Zonderman Journal: Ann Neurol Date: 2006-12 Impact factor: 10.422
Authors: Timo Grimmer; Maximilian Faust; Florian Auer; Panagiotis Alexopoulos; Hans Förstl; Gjermund Henriksen; Robert Perneczky; Christian Sorg; Behrooz H Yousefi; Alexander Drzezga; Alexander Kurz Journal: Neurobiol Aging Date: 2012-03-10 Impact factor: 4.673
Authors: Madhav Thambisetty; E Jeffrey Metter; An Yang; Hillary Dolan; Christopher Marano; Alan B Zonderman; Juan C Troncoso; Yun Zhou; Dean F Wong; Luigi Ferrucci; Josephine Egan; Susan M Resnick; Richard J O'Brien Journal: JAMA Neurol Date: 2013-09-01 Impact factor: 18.302
Authors: May A Beydoun; Nicole Noren Hooten; Ana I Maldonado; Hind A Beydoun; Jordan Weiss; Michele K Evans; Alan B Zonderman Journal: J Nutr Date: 2022-02-08 Impact factor: 4.798
Authors: Matthew K Taylor; Debra K Sullivan; Jessica E Keller; Jeffrey M Burns; Russell H Swerdlow Journal: Front Neurosci Date: 2022-06-16 Impact factor: 5.152
Authors: Tatjana Rundek; Hannah Gardener; Anita Seixas Dias Saporta; David A Loewenstein; Ranjan Duara; Clinton B Wright; Chuanhui Dong; Bonnie Levin; Mitchell S V Elkind; Ralph L Sacco Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Emily J Van Etten; Pradyumna K Bharadwaj; Lauren A Nguyen; Georg A Hishaw; Theodore P Trouard; Gene E Alexander Journal: Neurobiol Aging Date: 2020-06-19 Impact factor: 5.133